Press & Media Coverage
Catch up on our latest press coverage
[Infographic] MagSense® Imaging Agent Technology Overview
Imagion Biosystems (ASX:IBX) is a biotech company dedicated to improving healthcare through the earlier detection of cancer and other diseases. We are using our proprietary
April 2023 Investor Newsletter
We are continuing the momentum from our positive phase 1 trial results and are pleased to have recently released our latest updates in our April
Pitt Street Research Conducts Market Research Report on Imagion – April 2023
Pitt Street Research has published a 27-page overview report on Imagion Biosystems, Limited. This detailed report includes close examinations of the company’s business and investment
Non-renounceable Entitlement Offer – Extension of Closing Date
MELBOURNE – Imagion Biosystems (ASX:IBX, Imagion or the Company) refers to its announcement titled ‘Non-renounceable Entitlement Offer’ dated 7 March 2023 in relation to the
Imagion to proceed to file an IND for the MagSense HER2 Imaging Agent following FDA feedback
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update
Imagion Chats with 180 Markets on the Future of Cancer Detection
Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.